Abstracts tagged "osteoporosis"

Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 1045 • ACR Convergence 2025
Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
Hongke Wu¹, Ye Liu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: : Early adherence data for newly approved drugs guide clinical management, yet small cohorts hamper conventional analyses. Romosozumab (Romo), licensed April 2019 for high-risk…
Abstract Number: 2116 • ACR Convergence 2025
Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Giovanni Adami¹, Mariana Diz Lopes², Martina Tinelli², Angela Bonalumi², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Bone damage is a key feature of multiple myeloma (MM). Romosozumab (ROMO), a sclerostin inhibitor, has dual anabolic and antiresorptive properties and may offer…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
Abstract Number: 1054 • ACR Convergence 2025
Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Ye Liu¹, Hongke Wu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Polypharmacy is a major concern in osteoporosis (OP) management, especially in older adults. Romosozumab (romo), approved in April 2019, is a parenteral OP medicine…
Abstract Number: 2117 • ACR Convergence 2025
Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
Giovanni Adami¹, Kenneth Saag², Gary Cutter³, Rahima Begum³, Elizabeth Dye⁴, Phillip Foster⁵, Camilla Benini⁶, Carmela Dartizio⁶, Davide Gatti⁶ and Maria I. ("Maio") Danila⁷, ¹University of Verona, Italy, Verona, Italy, ²The University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴UAB, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Verona, Verona, Italy, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Prompt anti-resorptive treatment with bisphosphonates after denosumab discontinuation is generally recommended. Glucocorticoid users may not require longer term denosumab and are at greater fracture…
Abstract Number: 0345 • ACR Convergence 2025
Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Hashem Cheema¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe bay NHS foundation trust, Manchester, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Low socioeconomic status is associated with.an increase in osteoporosis and fracture risk respectively. A multitude of factors have been proposed including income, educational attainment…
Abstract Number: 1112 • ACR Convergence 2025
Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Manush Sondhi¹, Namrata Singh², Julie Carkin¹ and Grant Hughes³, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³University of Washington, Lynnwood, WA
Background/Purpose: The cardiovascular risks associated with osteoporosis medications remain incompletely understood. Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular…
Abstract Number: 2121 • ACR Convergence 2025
Prevention of Bone Mass Loss Associated With Aromatase Inhibitors in Breast Cancer. A Study in Real-World Clinical Practice.
Lucía Paz Liñeira¹, Beatriz Villapún Burgoa¹, Isabel Castrejón Fernández², José María álvaro-Gracia álvaro³, Teresa González Hernández¹, Sara López Tarruella¹ and Yolanda Jerez gilarranz¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ³Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Department of Medicine, Complutense University, Madrid, Spain., Madrid, Madrid, Spain
Background/Purpose: Treatment with aromatase inhibitors (AIs) in patients with breast cancer is associated with accelerated bone mineral density (BMD) loss, leading to an increased risk…
Abstract Number: 0346 • ACR Convergence 2025
Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
José Rodríguez gago¹, Carolina Tornero², Lina León³, María Luisa González-Casaus³, Luisa Fernanda Giraldo³, Gloria del Peso³, Diego Garrido³, Teresa López³, Mónica Coronado³, María Auxiliadora Bajo⁴, Sara García³, María Gema Serrano³, Marta Ossorio³, Alejandro Balsa³ and Pilar Aguado³, ¹Hospital Universitario La Paz, MADRID, ²Hospital La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Hospital Universitario de la Princesa - ISS Princesa, Madrid, Spain
Background/Purpose: Chronic kidney disease (CKD) is linked to increased vascular comorbidity and fracture risk. This study aims to assess bone status in CKD patients versus…
Abstract Number: 1313 • ACR Convergence 2025
Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
Jonathan Barnes¹, Hamzah Amin² and marwan Bukhari³, ¹Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Steroids are used in a proportion of patients with rheumatoid arthritis (RA). Steroids are known to cause a decrease in bone mineral density (BMD),…
Abstract Number: 2122 • ACR Convergence 2025
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Maryia Nikitsina¹, Cristina Valero², Miren Uriarte Ecenarro³, Ana M Ortiz³, María Ahijón Lana³, Irene Llorente³, Marina Dueñas-Ochoa⁴, Juan C Saez⁵, EVA GLORIA TOMERO MURIEL⁶, Esther Vicente-Rabaneda⁶, Isidoro Gonzalez-Alvaro⁷, Rosario Garcia Vicuña⁶ and Santos Castañeda⁸, ¹University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain, ⁴Hospital La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Romosozumab (RSZ) is a dual osteoanabolic agent that stimulates bone formation and reduces bone resorption, emerging as a promising option for treating osteoporosis (OP)…
Abstract Number: 0347 • ACR Convergence 2025
Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Kabyar Cho¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Coeliac disease (CD) is an autoimmune disease, which has been widely reported to be associated with reduced bone mineral density (BMD), leading to an…
Abstract Number: 1373 • ACR Convergence 2025
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Osteoporosis is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF)…
Abstract Number: 2123 • ACR Convergence 2025
Sclerostin in Aging Bone and Muscle: A Comparative Study of Osteoporosis, Sarcopenia, and Osteosarcopenia
Mohamed Tharwat Hegazy¹, Fatma Fayed¹, Shirihan Mahgoub¹, Yasmin El Ebrashy² and Maha Hossam Al-Din Ibrahim¹, ¹Faculty of Medicine, Cairo University, Cairo, Egypt, ²National institute of Diabetes and Endocrinology, Cairo, Egypt
Background/Purpose: Osteoporosis, sarcopenia, and frailty are the 3 determinants of aging. A novel syndrome of combined osteosarcopenia has negative health outcomes among geriatric populations. In…

1
2
3
…
23
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].